EBOS Group Limited (EBOS) notes the announcement by the Australian Competition and Consumer Commission (ACCC) today that it will not oppose the proposed acquisition of LifeHealthcare announced on 9 December 2021.
The transaction remains subject to satisfaction of certain conditions precedent and the parties continue to work diligently towards completion of the transaction, which is expected in FY22.
The ACCC will not oppose the proposed acquisition of Australian Pacific Health Supplies TopCo1 Pty Limited and its subsidiaries (Pacific Health Group) by EBOS Group Limited (ASX: EBO), through its subsidiary EBOS Medical Devices Australia Pty Limited.
EBOS and Pacific Health Group distribute a range of medical devices to private and public hospitals and to clinicians. Pacific Healt h Group also manufactures and distributes allografts through its Australian Biotechnologies business. In general, the majority of the parties’ offerings are complementary and not in direct competition.
A copy of the statement by the ACCC is attached.
Comments from our readers
No comments yet
Add your comment:
Related News:
NZAS Sign Long Term Contracts
Amended - IFT230 Maturity and Exchange for IFT350
Synlait forecast milk price update
Chorus submits 2023 fibre regulatory report
Infratil Infrastructure Bond Exchange Offer opens
May 31st Morning Report
NZAS and Mercury sign long-term agreement, creating opportunity for future investment in renewables
Meridian and NZAS sign long term contracts
ArborGen Holdings Results for Year Ended 31 March 2024
BAI - Full unaudited results to 31 March 2024